Clovis Oncology (CLVS) Tops Q3 EPS by 10c

Clovis Oncology (NASDAQ: CLVS) reported Q3 EPS of ($0.89), $0.10 better than the analyst estimate of ($0.99). Revenue for the quarter came in at $38.8 million versus the consensus estimate of $42.64 million.

For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Marpai, Inc. (MRAI) Misses Q2 EPS by 18c
• Eos Energy Enterprises (EOSE) PT Lowered to $5 at B.Riley